

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司
SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2005)

INSIDE INFORMATION
CREDIT RATING ON TENDER REGARDING PROCUREMENT
OF BROMHEXINE HYDROCHLORIDE INJECTION
AND
RESUMPTION OF TRADING

This announcement is made by SSY Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap 571 of the laws of Hong Kong).

CREDIT RATING ON TENDER REGARDING PROCUREMENT OF BROMHEXINE HYDROCHLORIDE INJECTION

On 14 August 2024, the Company received three notices issued to Shijiazhuang No. 4 Pharmaceutical Co., Ltd. (“**Shijiazhuang No. 4**”, a wholly-owned subsidiary of the Company) from the Hainan Province Public Resources Trading Services Centre* (海南省公共資源交易服務中心, the “**Hainan Centre**”), Hebei Province Medicine and Medical Equipment Centralised Procurement Centre* (河北省醫用藥品器械集中採購中心, the “**Hebei Centre**”) and Ningxia Hui Autonomous Region Public Resources Trading Services Centre* (寧夏回族自治區公共資源交易服務中心, the “**Ningxia Centre**”) respectively (the “**Notices**”). It is stated in the Notices that Shijiazhuang No. 4 was found to have tendering deficiency in the credit rating by the Hainan Centre, Hebei Centre and Ningxia Centre in respect of Shijiazhuang No. 4’s Bromhexine Hydrochloride Injection.

The Notices ranked the Shijiazhuang No. 4 or its produced Bromhexine Hydrochloride Injection as under serious breach of trust pursuant to Clause 3.7 of Discretionary Benchmarks for Medicine Prices and Procurement Credit Ratings (2020 version)* (醫藥價格和招採信用評級的裁量基準(2020版)) in Hainan, Hebei and Ningxia. Apart from Hainan, Hebei and Ningxia, Shijiazhuang No. 4's Bromhexine Hydrochloride Injection has also been sold in 6 other provinces/municipal including Fujian, Shanghai, Jiangxi, Zhejiang, Xinjiang and Yunnan in Mainland China (collectively, the “**9 Provinces/Municipal**”) under the National Centralized Medicine Procurement (“**National Centralized Procurement**”). The Company considers the sales of Shijiazhuang No. 4's Bromhexine Hydrochloride Injection under the National Centralized Procurement in the 9 Provinces/Municipal will be affected, as similar notices may also be issued in the 6 other provinces. However, it is in the Group's business plan to focus on expanding the sales of Shijiazhuang No. 4's Bromhexine Hydrochloride Injection in other parts of Mainland China other than the 9 Provinces/Municipal. As such, as at the date of this announcement, the Company considers that the Notices have no material adverse effect on the operations or financial position of the Group as a whole.

The Group is committed to the development of sustainable operations through the maintenance of good corporate governance and an effective risk management framework. The Company will continue to strengthen its compliance standards, including but not limited to monitoring and control of its operational practices under its established anti-corruption policies, so as to ensure that the operations of the Group will be guided by the principles of fairness and integrity.

Further announcement(s) in relation to the sale and distribution of the Group's Bromhexine Hydrochloride Injection will be made by the Company as and when appropriate.

RESUMPTION OF TRADING

At the request of the Company, trading in the shares of the Company on the Stock Exchange was halted with effect from 9:30 a.m. on Wednesday, 14 August 2024 pending the release of this announcement. Application has been made by the Company to the Stock Exchange for the resumption of trading in the shares of the Company on the Stock Exchange with effect from 9:00 a.m. on Thursday, 15 August 2024.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

On behalf of the Board

Chow Hing Yeung

Executive Director and Company Secretary

Hong Kong, 14 August 2024

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo and Mr. Chow Hing Yeung as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.

** For identification purposes only*